Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Spartanburg, South Carolina 29303


The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD. This study is designed to look at how well NVA237 improves the ability to exercise in patients with moderate to severe COPD.


Inclusion Criteria: - Male or female adults (aged 40 years and over) with a clinical diagnosis of moderate to severe COPD with a smoking history of at least 10 cigarettes pack years. - Patients with a post-bronchodilator FEV1 ≥35% and < 70% of the predicted normal, and post-bronchodilator FEV1/FVC < 0.7 during screening. - Increase in FEV1 from Pre-bronchodilator to Post-bronchodilator assessment of at least 5% Exclusion Criteria: - Pregnant or nursing mothers, women of child bearing potential unless using a reliable contraception method, Cardiac (heart) disorders, history of asthma, requiring oxygen therapy, treatment with certain COPD medication, on another investigational study, limitations on the exercise test due to non-respiratory conditions. - Other criteria applies



Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals

Backup Contact:


Location Contact:

Spartanburg, South Carolina 29303
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.